{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:53:58Z","timestamp":1790052838441,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":1012,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1111\/ajt.15661","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T13:53:46Z","timestamp":1571925226000},"page":"463-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody"],"prefix":"10.1016","volume":"20","author":[{"given":"Pascal","family":"Espi\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanLing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Sickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige","family":"Chokot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mergentaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Ristov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Milojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Verles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Groenewegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Auger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Avrameas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Tomek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Hernandez-Illas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1111\/ajt.15661_bib1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/ajt.13377","article-title":"A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion","volume":"15","author":"Cordoba","year":"2015","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1111\/ajt.15661_bib2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/01.tp.0000286058.79448.c7","article-title":"A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys","volume":"84","author":"Imai","year":"2007","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.15661_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1111\/ajt.15661_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br J Haematol."},{"issue":"1","key":"10.1111\/ajt.15661_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.180.1.157","article-title":"gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory","volume":"180","author":"Foy","year":"1994","journal-title":"J Exp Med."},{"issue":"3","key":"10.1111\/ajt.15661_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/1074-7613(94)90095-7","article-title":"The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation","volume":"1","author":"Kawabe","year":"1994","journal-title":"Immunity."},{"issue":"5","key":"10.1111\/ajt.15661_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/1074-7613(94)90073-6","article-title":"Mice deficient for the CD40 ligand","volume":"1","author":"Xu","year":"1994","journal-title":"Immunity."},{"issue":"5","key":"10.1111\/ajt.15661_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.TP.0000116563.72763.83","article-title":"Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation","volume":"77","author":"Schuler","year":"2004","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15661_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000116392.72152.75","article-title":"Monotherapy with the novel human anti-CD154 monoclonal antibody AB1793 in rhesus monkey renal transplantation model","volume":"77","author":"Kanmaz","year":"2004","journal-title":"Transplantation."},{"key":"10.1111\/ajt.15661_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/76251","article-title":"Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process","volume":"6","author":"Mauri","year":"2000","journal-title":"Nat Med."},{"issue":"1","key":"10.1111\/ajt.15661_bib11","first-page":"192","article-title":"Nonclinical safety assessment of CFZ533, a Fc-silent anti-CD40 antibody, in cynomolgus monkeys","volume":"166","author":"Ulrich","year":"2018","journal-title":"Toxicol Sci."},{"issue":"12","key":"10.1111\/ajt.15661_bib12","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant."},{"issue":"suppl 3","key":"10.1111\/ajt.15661_bib13","article-title":"CFZ533, a new anti-CD40 mAB demonstrates comparable efficacy and better renal function versus tacrolimus in de-novo CNI-free kidney transplantation [abstract]","volume":"17","author":"Nashan","year":"2017","journal-title":"Am J Transplant."},{"issue":"suppl 10","key":"10.1111\/ajt.15661_bib14","article-title":"The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren\u2019s syndrome: a phase IIa double-blind, placebo-controlled randomized trial [abstract]","volume":"69","author":"Fisher","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1111\/ajt.15661_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1742-7843.2009.00513.x","article-title":"On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models","volume":"106","author":"Lowe","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"6","key":"10.1111\/ajt.15661_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"10.1111\/ajt.15661_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today."},{"issue":"6","key":"10.1111\/ajt.15661_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.copbio.2009.10.013","article-title":"The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies","volume":"20","author":"Muller","year":"2009","journal-title":"Curr Opin Biotechnol."},{"key":"10.1111\/ajt.15661_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejps.2009.09.007","article-title":"Dynamics of target-mediated drug disposition","volume":"38","author":"Peletier","year":"2009","journal-title":"Eur J Pharm Sci."},{"issue":"5","key":"10.1111\/ajt.15661_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","article-title":"Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification","volume":"39","author":"Peletier","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"10.1111\/ajt.15661_bib21","doi-asserted-by":"crossref","first-page":"32801","DOI":"10.1074\/jbc.M209993200","article-title":"Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme","volume":"278","author":"Contin","year":"2003","journal-title":"J Biol Chem."},{"key":"10.1111\/ajt.15661_bib22","doi-asserted-by":"crossref","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev. 2018. https:\/\/doi.org\/10.1016\/j.addr.2018.12.005.","DOI":"10.1016\/j.addr.2018.12.005"},{"issue":"suppl 3","key":"10.1111\/ajt.15661_bib23","article-title":"Cni-free therapy with iscalimab (anti-cd40 mAb) preserves allograft histology compared to standard of care after kidney transplantation [Abstract]","volume":"19","author":"Farkash","year":"2019","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15661_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.0105-2896.2005.00229.x","article-title":"Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features","volume":"203","author":"Lougaris","year":"2005","journal-title":"Immunol Rev."},{"issue":"1","key":"10.1111\/ajt.15661_bib25","first-page":"57","article-title":"New monoclonal antibodies in renal transplantation","volume":"55","author":"Vincenti","year":"2003","journal-title":"Minerva Urol Nefrol."},{"key":"10.1111\/ajt.15661_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a \u03b23 integrin-dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat Med."},{"issue":"2","key":"10.1111\/ajt.15661_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-017-2362-8","article-title":"Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases","volume":"74","author":"Albach","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"10.1111\/ajt.15661_bib28","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/ajt.12082","article-title":"A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects","volume":"13","author":"Goldwater","year":"2013","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15661_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"issue":"Suppl 1","key":"10.1111\/ajt.15661_bib30","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10875-012-9768-y","article-title":"The immunologic functions of the neonatal Fc receptor for IgG","volume":"33","author":"Rath","year":"2013","journal-title":"J Clin Immunol."},{"issue":"1","key":"10.1111\/ajt.15661_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11095-005-8814-3","article-title":"Pharmacokinetics\/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers","volume":"23","author":"Ng","year":"2006","journal-title":"Pharm Res."},{"key":"10.1111\/ajt.15661_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jcph.4","article-title":"The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model","volume":"53","author":"Zhao","year":"2013","journal-title":"J Clin Pharmacol."},{"issue":"4","key":"10.1111\/ajt.15661_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.TP.0000440951.29757.bd","article-title":"Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys","volume":"97","author":"Ma","year":"2014","journal-title":"Transplantation."},{"issue":"1","key":"10.1111\/ajt.15661_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-0029-1224151","article-title":"CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells","volume":"118","author":"Chatzigeorgiou","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"10.1111\/ajt.15661_bib35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/07853890.2010.495951","article-title":"The pattern of inflammatory\/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time","volume":"42","author":"Chatzigeorgiou","year":"2010","journal-title":"Ann Med."},{"key":"10.1111\/ajt.15661_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12863-015-0279-8","article-title":"The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus","volume":"16","author":"Chen","year":"2015","journal-title":"BMC Genet."},{"key":"10.1111\/ajt.15661_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2249.2002.01752.x","article-title":"CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sj\u00f6gren\u2019s syndrome patients indicating their intrinsic activation","volume":"127","author":"Dimitriou","year":"2002","journal-title":"Clin Exp Immunol."},{"issue":"7","key":"10.1111\/ajt.15661_bib38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","article-title":"Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sj\u00f6gren\u2019s syndrome","volume":"78","author":"Wieczorek","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1111\/ajt.15661_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/art.1780400117","article-title":"Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides","volume":"40","author":"Yellin","year":"1997","journal-title":"Arthritis Rheum."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15661","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522221996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522221996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:27:57Z","timestamp":1761629277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522221996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1600613522221996"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15661","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}